Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

NCT05659290 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Fruquintinib alternating with Bevacizumab plus Capecitabine
DRUG: Bevacizumab plus Capecitabine

Sponsor

Nanfang Hospital, Southern Medical University